Literature DB >> 18220972

HIV protease inhibitors impact on apoptosis.

Stacey A Rizza1, Andrew D Badley.   

Abstract

HIV protease inhibitors are the backbone of HIV therapy. In addition to blocking intracellular HIV protease and dramatically decreasing viral burden, the protease inhibitors also regulate apoptosis. A growing body of data has confirmed the immunomodulatory effects of HIV protease inhibitors which block CD4+ and CD8+ T cell death in models of HIV infection. The mechanism of this apoptosis inhibition is still under active investigation and supported by several proposed hypothesis for how they alter the fate of the cell. More recently, the anti-apoptotic effects of the HIV protease inhibitors has been extended to the non-HIV, non-immune cell, whereby protease inhibitors prevent apoptosis, and disease, in animal models of sepsis, hepatitis and stroke. Interestingly, when HIV protease inhibitors are used at supra-therapeutic concentrations, they exert pro-apoptotic effects. This has been demonstrated in a number of tumor models. Although it is unclear how HIV protease inhibitors can induce apoptosis at increased concentrations, future research will define the targets of the immunomodulation and reveal the full clinical potential of this intriguing class of drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220972      PMCID: PMC3149800          DOI: 10.2174/157340608783331443

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  45 in total

1.  Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.

Authors:  E M Sloand; J Maciejewski; P Kumar; S Kim; A Chaudhuri; N Young
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals.

Authors:  S Chavan; S Kodoth; R Pahwa; S Pahwa
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

3.  Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

Authors:  B N Phenix; J B Angel; F Mandy; S Kravcik; K Parato; K A Chambers; K Gallicano; N Hawley-Foss; S Cassol; D W Cameron; A D Badley
Journal:  AIDS Res Hum Retroviruses       Date:  2000-04-10       Impact factor: 2.205

4.  Prediction of the tertiary structure of a caspase-9/inhibitor complex.

Authors:  K C Chou; A G Tomasselli; R L Heinrikson
Journal:  FEBS Lett       Date:  2000-03-31       Impact factor: 4.124

5.  Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.

Authors:  S Kravcik; A Magill; B Sanghvi; R Ogden; W D Cameron; R Lewis; G Yu; A D Badley
Journal:  HIV Clin Trials       Date:  2001 Mar-Apr

6.  HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells.

Authors:  F F Weichold; J L Bryant; S Pati; O Barabitskaya; R C Gallo; M S Reitz
Journal:  J Hum Virol       Date:  1999 Sep-Oct

7.  Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Authors:  M A Albrecht; R J Bosch; S M Hammer; S H Liou; H Kessler; M F Para; J Eron; H Valdez; M Dehlinger; D A Katzenstein
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

8.  Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

Authors:  B N Phenix; J J Lum; Z Nie; J Sanchez-Dardon; A D Badley
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

9.  HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism.

Authors:  W Lu; J M Andrieu
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

10.  HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.

Authors:  M Lichtner; F Mengoni; C M Mastroianni; I Sauzullo; R Rossi; M De Nicola; V Vullo; L Ghibelli
Journal:  Apoptosis       Date:  2006-05       Impact factor: 4.677

View more
  16 in total

1.  Low CD4+ T-cell levels and B-cell apoptosis in vertically HIV-exposed noninfected children and adolescents.

Authors:  Maristela Miyamoto; Silvana D Pessoa; Erika Ono; Daisy M Machado; Reinaldo Salomão; Regina C de M Succi; Savita Pahwa; Maria Isabel de Moraes-Pinto
Journal:  J Trop Pediatr       Date:  2010-04-13       Impact factor: 1.165

2.  Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.

Authors:  A Re; G Gini; M Rupolo; A Levis; A Bandera; A M Liberati; P Tozzi; C Cattaneo; S Casari; C Skert; C Bocci; M Spina; B Allione; L Verga; M Michieli; C Almici; P F Leali; U Tirelli; G Rossi
Journal:  Bone Marrow Transplant       Date:  2017-10-09       Impact factor: 5.483

3.  The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

Authors:  Mark A Wallet; Caroline M Reist; Julie C Williams; Sofia Appelberg; Giorgio L Guiulfo; Brent Gardner; John W Sleasman; Maureen M Goodenow
Journal:  J Leukoc Biol       Date:  2012-07-11       Impact factor: 4.962

4.  Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.

Authors:  Ansgar Brüning; Petra Burger; Marianne Vogel; Andrea Gingelmaier; Klaus Friese; Alexander Burges
Journal:  Invest New Drugs       Date:  2009-06-26       Impact factor: 3.850

5.  Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy.

Authors:  Hailiu Yang; Joseph Nkeze; Richard Y Zhao
Journal:  Cell Biosci       Date:  2012-09-12       Impact factor: 7.133

6.  In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.

Authors:  Pasqua Gramegna; Tiziana Latronico; Maria Teresa Branà; Gaetano Di Bari; Fabio Mengoni; Valeria Belvisi; Maria T Mascellino; Miriam Lichtner; Vincenzo Vullo; Claudio M Mastroianni; Grazia M Liuzzi
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

7.  Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.

Authors:  Sulggi A Lee; Sushama Telwatte; Hiroyu Hatano; Angela D M Kashuba; Mackenzie L Cottrell; Rebecca Hoh; Teri J Liegler; Sophie Stephenson; Ma Somsouk; Peter W Hunt; Steven G Deeks; Steven Yukl; Radojka M Savic
Journal:  J Acquir Immune Defic Syndr       Date:  2020-04-15       Impact factor: 3.771

Review 8.  Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV.

Authors:  Nathan W Cummins; Andrew D Badley
Journal:  Cell Mol Life Sci       Date:  2012-12-30       Impact factor: 9.261

9.  The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.

Authors:  Ansgar Brüning; Martina Rahmeh; Andrea Gingelmaier; Klaus Friese
Journal:  Mol Cancer       Date:  2010-01-27       Impact factor: 27.401

10.  Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.

Authors:  Jan Vesterbacka; Piotr Nowak; Babilonia Barqasho; Samir Abdurahman; Jessica Nyström; Staffan Nilsson; Hiroyuki Funaoka; Tatsuo Kanda; Lars-Magnus Andersson; Magnus Gisslèn; Anders Sönnerborg
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.